Literature DB >> 14664652

Excessive daytime sleepiness and sleep disturbances in patients with neurological diseases: epidemiology and management.

Svenja Happe1.   

Abstract

Up to 12% of the general population experience excessive daytime sleepiness (EDS), with increasing prevalence in the elderly. EDS may lead to cognitive impairment, resulting in inattentiveness, poor memory, mood disorders and an increased risk of accidents. As a result, quality of life is reduced in most patients with EDS as well as in their caregiving spouses. There are a variety of causes leading to EDS, including CNS pathology, neurological dysfunction, associated sleep disorders with insufficient or fragmented sleep, and drug therapy. Since EDS accompanies many neurological disorders, such as neurodegenerative and neuromuscular diseases, neurologists should be familiar with the diagnosis, its major causes and with treatment options. The main focus of this article is on movement disorders, neuromuscular diseases, multiple sclerosis, dementia, cerebrovascular diseases, head and brain trauma, pain and epilepsy. General management strategies for EDS in all these neurological diseases include sleep hygiene aspects such as extensions of noctural time in bed and frequent naps during the day. Pharmacological treatment is generally achieved with stimulants such as amphetamine, methylphenidate and pemoline, or newer compounds such as modafinil.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14664652     DOI: 10.2165/00003495-200363240-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  117 in total

1.  Pupillographic assessment of sleepiness in sleep-deprived healthy subjects.

Authors:  B Wilhelm; H Wilhelm; H Lüdtke; P Streicher; M Adler
Journal:  Sleep       Date:  1998-05-01       Impact factor: 5.849

2.  Epidemiology of restless legs symptoms in adults.

Authors:  B Phillips; T Young; L Finn; K Asher; W A Hening; C Purvis
Journal:  Arch Intern Med       Date:  2000-07-24

3.  Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine.

Authors:  P M Rossini; P Pasqualetti; C Pozzilli; M G Grasso; E Millefiorini; A Graceffa; G A Carlesimo; G Zibellini; C Caltagirone
Journal:  Mult Scler       Date:  2001-12       Impact factor: 6.312

Review 4.  Disorders of excessive daytime sleepiness--an update.

Authors:  B El-Ad; A D Korczyn
Journal:  J Neurol Sci       Date:  1998-01-08       Impact factor: 3.181

5.  Symposium: Normal and abnormal REM sleep regulation: REM sleep behaviour disorder: an update on a series of 96 patients and a review of the world literature.

Authors: 
Journal:  J Sleep Res       Date:  1993-12       Impact factor: 3.981

6.  Progressive dementia and hypersomnolence with dream-enacting behavior: oneiric dementia.

Authors:  Jean E Cibula; Stephan Eisenschenk; Michael Gold; Thomas A Eskin; Robin L Gilmore; Kenneth M Heilman
Journal:  Arch Neurol       Date:  2002-04

7.  Evaluation of somnolence in Parkinson's disease: comparison with age- and sex-matched controls.

Authors:  E K Tan; S Y Lum; S M C Fook-Chong; M L Teoh; Y Yih; L Tan; A Tan; M C Wong
Journal:  Neurology       Date:  2002-02-12       Impact factor: 9.910

8.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

9.  Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease.

Authors:  Padraig E O'Suilleabhain; Richard B Dewey
Journal:  Arch Neurol       Date:  2002-06

10.  The effect of sleep on the dyskinetic movements of Parkinson's disease, Gilles de la Tourette syndrome, Huntington's disease, and torsion dystonia.

Authors:  D R Fish; D Sawyers; P J Allen; J D Blackie; A J Lees; C D Marsden
Journal:  Arch Neurol       Date:  1991-02
View more
  18 in total

Review 1.  Cataplexy associated with narcolepsy: epidemiology, pathophysiology and management.

Authors:  Michael J Thorpy
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 2.  Modafinil : a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder.

Authors:  Gillian M Keating; Michael J Raffin
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  Comparative levels of excessive daytime sleepiness in common medical disorders.

Authors:  Alice F Stroe; Thomas Roth; Catherine Jefferson; David W Hudgel; Timothy Roehrs; Kenneth Moss; Christopher L Drake
Journal:  Sleep Med       Date:  2010-10       Impact factor: 3.492

4.  Noncontact Pressure-Based Sleep/Wake Discrimination.

Authors:  Lorcan Walsh; Sean McLoone; Joseph Ronda; Jeanne F Duffy; Charles A Czeisler
Journal:  IEEE Trans Biomed Eng       Date:  2016-10-25       Impact factor: 4.538

Review 5.  Sleep disturbances and fatigue in critically ill patients.

Authors:  Ellyn E Matthews
Journal:  AACN Adv Crit Care       Date:  2011 Jul-Sep

Review 6.  How vital is sleep in Huntington's disease?

Authors:  Anna O G Goodman; Roger A Barker
Journal:  J Neurol       Date:  2010-03-24       Impact factor: 4.849

7.  Sleep alterations in an environmental neurotoxin-induced model of parkinsonism.

Authors:  Kimberly A McDowell; Maria M Hadjimarkou; Shaun Viechweg; Avigail E Rose; Sarah M Clark; Paul J Yarowsky; Jessica A Mong
Journal:  Exp Neurol       Date:  2010-08-14       Impact factor: 5.330

8.  Identifying sleep disturbances in Huntington's disease using a simple disease-focused questionnaire.

Authors:  Anna O G Goodman; A Jennifer Morton; Roger A Barker
Journal:  PLoS Curr       Date:  2010-10-15

Review 9.  Evidence-based recommendations for the assessment and management of sleep disorders in older persons.

Authors:  Harrison G Bloom; Imran Ahmed; Cathy A Alessi; Sonia Ancoli-Israel; Daniel J Buysse; Meir H Kryger; Barbara A Phillips; Michael J Thorpy; Michael V Vitiello; Phyllis C Zee
Journal:  J Am Geriatr Soc       Date:  2009-05       Impact factor: 5.562

Review 10.  Autonomic dysfunction in multiple sclerosis.

Authors:  Carl-Albrecht Haensch; Johannes Jörg
Journal:  J Neurol       Date:  2006-02       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.